NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

June 25, 2022

7:30am – 5:00pm 

Earn up to 6.25 AMA PRA Category 1 Credits,™ Continuing Nursing Education (ANCC), and MOC accreditation

Register Here

Location

The Bidwell Marriott Portland
520 SW Broadway
Portland, OR 97205

_{NANETS does not facilitate a Group Room Block for Regional Conferences, all hotel rooms are book on own.}

Providers

Jointly Provided by the Oregon Health & Science University, Providence Cancer Institute, and the North American Neuroendocrine Tumor Society

Course Directors

Hagen Kennecke, MD, Providence Cancer Institute & Erik Mittra, MD, PhD, Oregon Health & Science University

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years, there was great variability in terms of treatment. The diagnosis, treatment and management of NETs are time-consuming, complex and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
• Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
• Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
• Recognize the clinical features associated with carcinoid syndrome
• Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
• Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors

Program

• • Hagen F. Kennecke, MD, Medical Director of Gastrointestinal (GI) Oncology, Providence Cancer Institute
    Erik S. Mittra, MD, PhD, Professor of Diagnostic Radiology, Oregon Health & Science University

• • Introduction to NETs
    Hagen F. Kennecke, MD, Medical Director of Gastrointestinal (GI) Oncology, Providence Cancer Institute
  • Conventional and Functional Imaging of NETs
    Nadine Mallak, MD, Assistant Professor, Director of Nuclear Medicine and Molecular Imaging Residency, Oregon Health & Science University
  • Moderated by:
    Erik S. Mittra, MD, PhD, Professor of Diagnostic Radiology, Oregon Health & Science University

• • Surgical Management of Small Bowel and Rectal NETs
    Maria Ximena Traa Kiely, MD, MPH, Colon and Rectal Surgeon, The Oregon Clinic
  • Liver and Pancreatic Surgery
    Rodney F. Pommier, MD, FACS, Professor of Surgery, Oregon Health & Science University
  • Interventional approaches for NETs
    Yilun Koethe, MD, Assistant Professor of Interventional Radiology, Oregon Health & Science University
  • Moderated by: 
    Flavio G. Rocha, MD, FACS, FSSO, Associate Professor of Surgery, Hedinger Chair and Division Head of Surgery, Oregon Health & Science University

• • Systemic Therapies
    David Zhen, MD, Assistant Professor, University of Washington School of Medicine; Assistant Professor, Clinical Research Division Fred Hutchinson Cancer Research Center
  • Clinical Trials
    Guillaume Pegna, MD, Assistant Professor of Medicine, Division of Hematology/Medical Oncology, Oregon Health and Science University
  • PRRT: Current Practice 
    Delphine Chen, MD, Director of Molecular Imaging, Seattle Cancer Care Alliance; Wil B. Nelp, MD Endowed Professorship in Nuclear Medicine; Professor, Department of Radiology, University of Washington School of Medicine
  • PRRT: Future Directions
    Erik S. Mittra, MD, PhD, Professor of Diagnostic Radiology, Oregon Health & Science University
  • Moderated by: 
    Hagen F. Kennecke, MD, Medical Director of Gastrointestinal (GI) Oncology, Providence Cancer Institute

• • Case Presentation
    Nancy Sharma, MD, Medical Oncologist, Hematologist, Swedish Cancer Institute
  • Hormonal Management and Symptom Control 
    Lauren Fishbein, MD, PhD, Associate Professor, Medicine-Endocrinology, Metabolism, Diabetes, University of Colorado Denver
  • Carcinoid Heart Disease
    Michael E. Layoun, MD, Cardiologist, Providence St. Vincent Medical Center
  • Surgical Treatment for CHD 
    Castigliano M. Bhamidipati, DO, PhD, MSc, FACS, Assistant Professor of Surgery, Oregon Health & Science University
  • Moderated by: 
    Nadine Mallak, MD, Assistant Professor, Director of Nuclear Medicine and Molecular Imaging Residency, Oregon Health & Science University

• • Pheo/Para Overview
    Lauren Fishbein, MD, PhD, Associate Professor, Medicine-Endocrinology, Metabolism, Diabetes, University of Colorado Denver
  • Imaging
    Nadine Mallak, MD, Assistant Professor, Director of Nuclear Medicine and Molecular Imaging Residency, Oregon Health & Science University
  • Surgical Management
    Michele L. Babicky, MD, Surgical Oncologist, The Oregon Clinic
  • Medical Management and Clinical Trials
    Jaydira Del Rivero, MD PhD, Physician Scientist in the Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health
  • Moderated by:
    Guillaume Pegna, MD, Assistant Professor of Medicine, Division of Hematology/Medical Oncology, Oregon Health and Science University

• • Hagen F. Kennecke, MD, Medical Director of Gastrointestinal (GI) Oncology, Providence Cancer Institute
    Erik S. Mittra, MD, PhD, Professor of Diagnostic Radiology, Oregon Health & Science University

Accreditation

This continuing education activity is provided through collaboration between the North American Endocrine Tumor Society (NANETS) and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, and nurses. A statement of participation is available for other attendees.

Physicians, Physician Assistants, and Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians for ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation enables the participant to earn up to 6.25 Medical Knowledge only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Use of Learner/Participant Data

Participation information will be shared with the applicable certifying board via ACCME PARS.

In order for MOC credit to be reported, evaluations must be completed prior to the close of evaluations.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NANETS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 6.25 hours of continuing nursing education credit.

 

Register Here

In-person registration is available onsite the day of the program and will be accommodated on a space-available basis

Registration fee:

NANETS Member

$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident

Non-Member

$95 - MD, PharmD, Doctoral Level 
$50 - Allied Health
Complimentary - Student/Fellow/Resident

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before June 3, 2022. On or after June 4, 2022, no refund will be made.

The Oregon Health & Science University, the Virginia Mason Medical Center and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.

Questions?

Please contact us with any questions.